How GLP-1 receptor agonists affect kidney disease in diabetes
Updated
Abstract
The FLOW study confirms a nephroprotective effect of semaglutide in diabetic kidney disease (DKD) patients with type 2 diabetes (T2DM).
- Optimal management of DKD includes glycemic control and medications such as renin-angiotensin system blockers and sodium-glucose cotransporter 2 inhibitors.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended to lower cardiovascular risk in high-risk T2DM patients.
- Certain GLP-1 RAs may also provide protective benefits for kidney health in patients with DKD.
- The FLOW study specifically analyzes renal outcomes with semaglutide compared to placebo.
Simplified
Funding
Competing interests
N. Paquot est coinvestigateur principal pour le CHU de Liège dans l’essai SURPASS-CVOT et déclare avoir reçu des honoraires comme orateur et/ou membre d’un conseil scientifique de la part des firmes AstraZeneca, Boehringer Ingelheim, Lilly, NovoNordisk, Fresenius et Sanofi.
PubMed